Molbio Diagnostics Ltd IPO: What You Should Know

The maker of the Truenat point-of-care PCR platform opens its Rs 939.70 crore mainboard issue on August 10 — a rare Indian diagnostics story with global reach, and a WHO endorsement

Molbio Diagnostics Ltd. (MDL), the developer of the Truenat portable PCR platform, opens for subscription on August 10 with the issue closing on August 12.

Molbio Diagnostics Ltd. (MDL) is one of the more distinctive Indian healthcare companies to come to the markets in recent years. It builds and sells point-of-care (POC) diagnostic devices that can test for infectious and non-communicable diseases in places where a traditional lab simply cannot operate — remote villages, mobile clinics, primary health centres, and battlefield-grade settings.

The product

The flagship product is Truenat, a portable, battery-operated real-time PCR platform that delivers results in about an hour. It works without a stable power supply, doesn’t need a fully equipped lab, and can be used by trained health workers rather than specialists. This is a big deal in a country where most diagnostic testing happens in a handful of urban labs, and even more so in low and middle-income countries around the world.

The Truenat platform consists of two portable instruments — Trueprep, which handles automated sample preparation, and Truelab, which runs the real-time PCR test in three variants (UnoDx, Duo, Quattro) that can perform one, two or four tests at a time. These devices work with disease-specific test kits that are shelf-stable at room temperature and single-use.

As of March 31, 2026, MDL offered molecular tests for 30 diseases through 43 assays, including tuberculosis, COVID, Hepatitis B and C, HIV and HPV. The Truenat platform is patented in over 100 countries, and its TB test chip is one of only two rapid molecular TB tests in the world endorsed by the World Health Organization for initial TB diagnosis and rifampicin resistance detection — a genuine differentiator that took 13 years of R&D to earn ICMR certification.

The company has sold over 12,500 devices in more than 90 countries. Beyond Truenat, MDL has expanded into radiology and digital pathology through its subsidiaries Prognosys (ultraportable X-ray systems, C-arm systems, veterinary imaging) and OptraScan (digital pathology scanners, AI-powered analysis, telepathology), and a partnership with UE Lifesciences for breast health screening.

The market opportunity is large and growing. Global POC testing was around USD 29.3 billion in 2025 and is projected to hit USD 67.1 billion by 2030 — a 17.9% CAGR. Infectious diseases alone cause around 1.5 million deaths globally each year, and diagnosis is often the bottleneck.

MDL runs six manufacturing facilities in India — two in Goa, one in Bengaluru, one in Vizag, one Prognosys plant in Bengaluru, and one OptraScan plant in Pune. Installed capacity is 5,400 devices and 39 million test kits per year. Capacity utilisation was 42.30% for devices and 58.25% for kits in FY26 — leaving meaningful room for growth.

Government and international aid agencies contribute the bulk of revenue — 84.56% in FY26. That is both an anchor and a risk. As of March 31, 2026, MDL had 1,225 payroll employees and 1,615 contract workers.

Issue Details

From the fresh proceeds, Rs 105.53 crore is earmarked for capex on R&D infrastructure, Rs 72.28 crore for capex on plant and machinery, and the balance for general corporate purposes.

Post-IPO, paid-up equity moves from Rs 11.28 crore to Rs 11.52 crore. Employees have been offered a discount of Rs 76 per share on the employee reservation portion of Rs 1.50 crore.

The promoter and selling stakeholder average cost of acquisition ranges widely from Rs NIL and Rs Negligible up to Rs 187.14 per share. This reflects earlier share issuances between Rs 651.46 and Rs 5,449.591 (between May 2021 and September 2024) and a 4-for-1 bonus issue in July 2025.

GMP Watch

Grey market interest has been strong, though it has cooled from its highs. Molbio Diagnostics IPO GMP made a high of Rs 220 on 7 August and a low of Rs 170 on 6 August. On the opening day, GMP stood at around Rs 132, suggesting an estimated listing price of Rs 939 — a premium of about 16% over the upper end of the price band of Rs 807.

Grey market activity across the run-up has ranged between roughly Rs 50 and Rs 220, reflecting evolving demand as the pricing and offer structure became clearer to investors. Do note that GMP is unofficial, unregulated by SEBI and can move quickly with sentiment — it is at best one input, not the basis for a decision.

Financial Performance

Revenue has grown from Rs 840.66 crore in FY24 to Rs 1,455.17 crore in FY26 — a healthy climb driven by higher device deployments, growing test kit volumes and the ramp-up of new disease assays. PAT has nearly doubled to Rs 164.14 crore in the same period.

Margins have moved less linearly. PAT margin peaked at 13.48% in FY25 and settled at 11.28% in FY26, and RoCE followed a similar pattern. Part of the FY26 dip likely reflects investment in R&D and expansion into new geographies and product lines — a trade-off for a company still building out its platform.

Average EPS over three years is Rs 13.18 and average RoNW is 14.46%. At the upper band of Rs 807, the P/E works out to 56.55x on FY26 earnings and 67.08x on FY25 — a rich multiple but not out of line with the diagnostics peer set. The issue is priced at a P/BV of 7.95 on pre-IPO NAV and 6.92 on post-IPO NAV of Rs 116.68 per share.

Listed peers Poly Medicure, Dr. Lal Pathlabs, Metropolis Healthcare and Vijaya Diagnostics trade at P/E multiples of 52.6, 57.6, 56.3 and 74.4 respectively (as of August 7, 2026) — though these are traditional diagnostic chains rather than platform companies, and not strict apples-to-apples comparisons.

Risks to Consider

The heavy dependence on government and international aid agencies — 91.60% of product revenue in FY24, moderating to 84.56% in FY26 — is a structural risk. Any policy shift, funding cut or change in public health priorities could hit sales meaningfully. This is exactly why revenue can be lumpy in POC diagnostics.

Working capital cycles are long. Government customers typically take time to pay, and receivables are reportedly over Rs 400 crore, with working capital days around 166. This is baked into the business model but ties up cash even as profits grow.

Contingent liabilities of Rs 168.74 crore as of March 31, 2026 are meaningful and deserve careful review in the RHP.

Raw material concentration is another concern. The company depends on a few key suppliers for critical inputs, and over 40% of raw materials are imported — leaving it exposed to currency swings and supply disruptions.

Borrowings have risen sharply following recent acquisitions, and integration risk with Prognosys and OptraScan is real.

The Price Point

Molbio Diagnostics is a rare Indian company — a globally patented POC diagnostics platform with WHO endorsement, presence in over 90 countries, and a recurring revenue model tied to test kits rather than one-off device sales. The Truenat platform genuinely fills a gap in the global healthcare system, and the addressable market is growing at nearly 18% a year.

The company enjoys a virtual monopoly in its Indian home market for POC molecular testing, and its oligopolistic global position — earned through 13 years of R&D and a deep patent moat — is hard to replicate. Growth into digital pathology and radiology via Prognosys and OptraScan gives the story additional legs.

That said, priced at 56.55x FY26 and 67.08x FY25 earnings, the issue is fully priced. The dependence on government funding and long working capital cycles need close watching. A GMP of around Rs 120-132 suggests moderate but reasonable listing interest.